AORTIC AND MITRAL VALVE CALCIFICATION IN PATIENTS WITH END-STAGE RENAL DISEASE

The Lancet ◽  
1987 ◽  
Vol 330 (8564) ◽  
pp. 875-877 ◽  
Author(s):  
E MAHER
Keyword(s):  
Mitral Valve ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Valve Calcification ◽  
Stage Renal Disease ◽  
End Stage ◽  
Mitral Valve Calcification

Cardiovascular Disease as a Late Complication of End-Stage Renal Disease in Children

2005 ◽  
Vol 25 (3_suppl) ◽  
pp. 123-126 ◽  
Author(s):  
Jaap Groothoff ◽  
Mariken Gruppen ◽  
Eric De Groot ◽  
Martin Offringa
Keyword(s):  
Cardiovascular Disease ◽  
Aortic Valve ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Arterial Wall ◽  
Aortic Valve Calcification ◽  
Cross Sectional ◽  
Valve Calcification ◽  
Stage Renal Disease ◽  
End Stage

♦ Objective To analyze the late cardiovascular outcome of end-stage renal disease (ESRD) in children. ♦ Design A nation-wide long-term follow-up study. Determinants of outcomes and causes of death were retrospectively assessed. Patients underwent assessment of overall health state, B- and M-mode ultrasound of the carotid arteries, and echocardiography for cross-sectional analysis. ♦ Results We analyzed the medical course of all 249 adult Dutch patients with ESRD onset between 1972 and 1992 at age 0 – 14 years, and who were born before 1979. Of the 187 living patients, 140 participated in the cross-sectional part of the study. The standardized mortality rate was 31.0. Overall 5-, 10-, and 20-year survival after ESRD onset was 87%, 82%, and 78%, respectively. Cardiovascular disease accounted for most deaths (41%). In the whole group, left ventricular hypertrophy (LVH), aortic valve calcification, and arterial wall stiffening were highly prevalent. LVH was associated with hypertension at time of assessment. Aortic valve calcification was strongly associated with a long total duration of peritoneal dialysis (β = 0.33, p < 0.001). Arterial wall pathology was not associated with current treatment modality. ♦ Conclusions As in adults, cardiovascular disease is the most important cause of death in children with ESRD. Stricter reduction of volume overload, prevention of high serum calcium–phosphate product, and more vigorous treatment of hypertension are important targets to improve cardiovascular survival in children with ESRD.

A Rare Cause of Mitral Valve Dysfunction in End-Stage Renal Disease

2020 ◽  
Vol 34 (12) ◽  
pp. 3469-3474
Author(s):  
Christine Choi ◽  
Quoc-Sy Nguyen ◽  
Perin Kothari ◽  
Ilona Juan ◽  
Paul S. Pagel
Keyword(s):  
Mitral Valve ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Valve Dysfunction ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Factors determining mitral valve dysfunction in patients who underwent surgical mitral valve replacement with bio-prosthetic valves

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
S Y Gwak ◽  
D Y Kim ◽  
J W Seo ◽  
I S Cho ◽  
S H Lee ◽  
...  
Keyword(s):  
Mitral Valve ◽  
Renal Disease ◽  
Pressure Gradient ◽  
Clinical Outcomes ◽  
End Stage Renal Disease ◽  
Hazard Ratio ◽  
Prosthetic Valves ◽  
Stage Renal Disease ◽  
End Stage

Abstract Background There is increasing Interest in bio-prosthetic MVD as recent advances in transcatheter MV interventions, but there is limited data. Objectives The aim of this study was to identify the factors determining mitral valve (MV) dysfunction (MVD) in patients who underwent MV replacement with bio-prosthetic valves. Also, we sought to investigate clinical outcomes in patients with bio-prosthetic MVD. Methods A total of 233 patients underwent surgical bio-prosthetic MV replacement between June 1996 and May 2015. Finally, 226 patients (mean age 66.9±11.5 years, 74.3% of women) were analyzed, excluding patients who followed-up for less than 5 years and patients whose baseline or follow-up echocardiography could not be analyzed. Clinical, echocardiographic, and laboratory data were collected early after the surgery and during follow-up. MVD was defined as an increase in mean gradient ≥5 mmHg with leaflet motion limitation and/or newly developed MV regurgitation during follow-up. Clinical outcome was defined as a composite of cardiovascular death, redo MV surgery or intervention, and hospitalization for heart failure. Results During a median of 102.0 months (interquartile range 72.0 to 132.0 months), 65 patients (28.8%) revealed MVD. 8 (12.3%) patients revealed predominant MV obstruction, and 57 (87.7%) showed predominant MV regurgitation. Factors associated with bio-prosthetic MVD by multivariate regression analysis were young age at operation (hazard ratio 0.97, 95% CI 0.95–0.99, p=0.001), end-stage renal disease (hazard ratio 4.29, 95% CI 1.45–12.71, p=0.007), elevated mean diastolic pressure gradient&gt;5.5 mmHg across the bio-prosthetic MV early after operation (hazard ratio 1.86, 95% CI 0.97–3.74, p=0.063) and anemia after operation (hazard ratio 0.84, 95% CI 0.74–0.95, p=0.007). However, the presence of hypertension, dyslipidemia, or porcine bio-prosthesis was not related to the bio-prosthetic MVD. Kaplan-Meier curves revealed significant differences in event-free survivals for the occurrence of bio-prosthetic MVD according to each factor (Figure 1). Patients with bio-prosthetic MVD showed significantly poor clinical outcomes compared with those without bio-prosthetic MVD (event-free survival 43.1% vs. 91.9%, log-rank p&lt;0.001) during the follow-up. Conclusions Young age at operation, end-stage renal disease, elevated mean pressure gradient early after the operation, and anemia after operation were associated with bio-prosthetic MVD in patients who underwent bio-prosthetic MV replacement. FUNDunding Acknowledgement Type of funding sources: None.

Sign in / Sign up

Export Citation Format

Share Document